---
category: news
title: "BioXcel Therapeutics to Present at Three Upcoming Investor Conferences"
excerpt: "May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches ... also developing BXCL502 as a potential therapy for chronic agitation in dementia ..."
publishedDateTime: 2022-05-05T11:02:00Z
originalUrl: "https://apnews.com/press-release/GlobeNewswire/business-health-54aadf3f267d6b6acf0d3f62a938dd5c"
webUrl: "https://apnews.com/press-release/GlobeNewswire/business-health-54aadf3f267d6b6acf0d3f62a938dd5c"
type: article
quality: 4
heat: -1
published: false

provider:
  name: Associated Press
  domain: apnews.com

topics:
  - AI in Healthcare
  - AI

related:
  - title: "Why BioXcel Therapeutics Shares Went Up 12.9% This Week"
    excerpt: "Shares of BioXcel Therapeutics (NASDAQ: BTAI), a commercial-stage biopharmaceutical company that uses artificial intelligence to develop neuroscience and immuno-oncology therapies, rose 12.9% this week,"
    publishedDateTime: 2022-05-05T20:54:00Z
    webUrl: "https://www.nasdaq.com/articles/why-bioxcel-therapeutics-shares-went-up-12.9-this-week"
    ampWebUrl: "https://www.nasdaq.com/articles/why-bioxcel-therapeutics-shares-went-up-12.9-this-week?amp"
    cdnAmpWebUrl: "https://www-nasdaq-com.cdn.ampproject.org/c/s/www.nasdaq.com/articles/why-bioxcel-therapeutics-shares-went-up-12.9-this-week?amp"
    type: article
    provider:
      name: Nasdaq
      domain: nasdaq.com
    quality: 54
  - title: "BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights"
    excerpt: "Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Top-line data readout in Q4 2022/early Q1 2023 for TRANQUILITY II Phase 3 trial evaluating BXCL501 in acute treatment of agitation associated with Alzheimer’s disease Extended cash runway into 2025 with $260 million strategic financing for IGALMI commercial launch and clinical and regulatory milestones U."
    publishedDateTime: 2022-05-09T11:03:00Z
    webUrl: "https://apnews.com/press-release/globe-newswire/covid-technology-health-business-mental-3717bf59c739265c231f90dcf287f725"
    type: article
    provider:
      name: Associated Press
      domain: apnews.com
    quality: 10
    images:
      - url: "https://apnews.com/images/PaidContent3.png"
        width: 700
        height: 450
        isCached: true

secured: "vtmzqLfdv7/Y81vYt+3HNC1mva9j7j+LckWpCdxuTGw9tDzTGH2acpbMjWEcE2Ku0tzjuxP998dNIQCZ1Lmiyc5gpH2dfhD+UQuHO9FFkPV05LuOd6th8mZ+ogL4l2e6vxEH4twDgyPU1PK12XLsWGaFR0riJotupZc0fiLluopOBZdd2PECk62WPLrGJ9LTt/UVUgeSZZeDEJ+wIomZckCxZLZpt3yQngm5LRBWZdlkO5cO7sTOUjHcD1E0uraFxaTt+IIU9oXwRL/C6mh5tKiezoxpgx/gSZI5yWuVBOaSj3mT6bhnd4zWg4n5X9ZTTeaDwZKg3x6i71FUOU46TCXIwb8PGfpXrRCFlGAfilE=;4vy79cqDYUPMdrkqRZZAOg=="
---

